Aptar to Present at 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025
AptarGroup (NYSE: ATR), a leader in drug and consumer product dosing, dispensing and protection technologies, has announced its upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. Stephan Tanda, President and CEO, will deliver a presentation at 12:45 p.m. EST. Executive Vice President and CFO Vanessa Kanu and Aptar Pharma President Gael Touya will also be in attendance. The presentation materials will be accessible to investors through the company's website at www.aptar.com.
AptarGroup (NYSE: ATR), un leader nelle tecnologie per il dosaggio, la distribuzione e la protezione di farmaci e prodotti di consumo, ha annunciato la sua prossima partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan il 16 gennaio 2025. Stephan Tanda, Presidente e CEO, presenterà alle 12:45 p.m. EST. Saranno presenti anche la Vice Presidente Esecutiva e CFO Vanessa Kanu e il Presidente di Aptar Pharma Gael Touya. I materiali della presentazione saranno accessibili agli investitori attraverso il sito web dell'azienda all'indirizzo www.aptar.com.
AptarGroup (NYSE: ATR), un líder en tecnologías de dosificación, dispensación y protección de medicamentos y productos de consumo, ha anunciado su próxima participación en la 43ª Conferencia Anual de Salud J.P. Morgan el 16 de enero de 2025. Stephan Tanda, Presidente y CEO, realizará una presentación a las 12:45 p.m. EST. También estarán presentes la Vicepresidenta Ejecutiva y CFO Vanessa Kanu y el Presidente de Aptar Pharma Gael Touya. Los materiales de la presentación estarán disponibles para los inversores a través del sitio web de la empresa en www.aptar.com.
AptarGroup (NYSE: ATR)는 약물 및 소비재의 투약, 배급 및 보호 기술의 선두주자로서, 2025년 1월 16일에 개최되는 제43회 J.P. Morgan 헬스케어 컨퍼런스에 참석할 예정이라고 발표했습니다. Stephan Tanda 사장 겸 CEO가 동부 표준시 기준으로 오후 12시 45분에 발표를 진행합니다. 이와 함께 Vanessa Kanu 수석 부사장 겸 CFO와 Aptar Pharma의 Gael Touya 사장도 참석할 예정입니다. 발표 자료는 회사 웹사이트 www.aptar.com를 통해 투자자들이 접근할 수 있습니다.
AptarGroup (NYSE: ATR), un leader dans les technologies de dosage, de distribution et de protection des médicaments et des produits de consommation, a annoncé sa prochaine participation à la 43e Conférence Annuelle J.P. Morgan sur la Santé le 16 janvier 2025. Stephan Tanda, Président et CEO, fera une présentation à 12h45 EST. La Vice-Présidente Exécutive et CFO Vanessa Kanu ainsi que le Président d'Aptar Pharma Gael Touya seront également présents. Les documents de présentation seront accessibles aux investisseurs via le site web de l'entreprise à l'adresse www.aptar.com.
AptarGroup (NYSE: ATR), ein führendes Unternehmen im Bereich Dosierung, Abgabe und Schutztechnologien für Arzneimittel und Konsumgüter, hat seine bevorstehende Teilnahme an der 43. J.P. Morgan Gesundheitskonferenz am 16. Januar 2025 angekündigt. Stephan Tanda, Präsident und CEO, wird um 12:45 Uhr EST eine Präsentation halten. Auch die Executive Vice President und CFO Vanessa Kanu sowie der Präsident von Aptar Pharma Gael Touya werden anwesend sein. Die Präsentationsmaterialien werden über die Unternehmenswebsite www.aptar.com für Investoren zugänglich sein.
- None.
- None.
Stephan Tanda, President and CEO, will present at 12:45 p.m. Eastern Standard Time. Vanessa Kanu, Executive Vice President and CFO and Gael Touya, President Aptar Pharma, will also be available.
A copy of the presentation will be made available on the Investors page at www.aptar.com.
About Aptar
Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in
This press release contains forward-looking statements. Expressions or future or conditional verbs such as “will” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250106991578/en/
Aptar Investor Relations Contact:
Mary Skafidas
mary.skafidas@aptar.com
+1 347 351 6407
Aptar Media Contact:
Katie Reardon
katie.reardon@aptar.com
+1 815 479 5671
Source: AptarGroup, Inc.
FAQ
When is AptarGroup (ATR) presenting at the J.P. Morgan Healthcare Conference 2025?
Who will represent ATR at the 2025 J.P. Morgan Healthcare Conference?
Where can investors access ATR's J.P. Morgan Healthcare Conference presentation?
Which annual J.P. Morgan Healthcare Conference will ATR attend in 2025?
